Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA

Inclusion Criteria: * Ability to understand and willingness to sign a written informed consent document. * Histologically confirmed Fibrolamellar hepatocellular carcinoma (FL-HCC) or other malignant disease in an adjuvant setting, defined as: * Presence of DNAJB1-PRKACA fusion transcript, assessed by RNA-based NGS or RT-PCR * Achievement of complete remission (CR) according to RECIST1.1 by any of the following therapeutic measures: * surgical procedures, * radiotherapy, * local therapeutic measures (e.g. TACE, SIRT, etc.) * systemic treatment (e.g. chemotherapy) * Age ≥ 12 years. Note: Subjects aged ≥ 12 years but \< 18 are eligible to enroll only after 6 adult patients have been enrolled in the study. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * Adequate laboratory values for * Absolute Lymphocyte Count \> 500 /µl * Platelets \> 50.000 /µl * Creatinine clearance GFR \> 30 ml/min * Alanine aminotransferase (ALT) and aminotransferase (AST) ≤ 5 times upper limit range * Bilirubin ≤ 3 mg/dl * Negative serological hepatitis B test or negative PCR in case of positive serological test without evidence of an active infection, negative testing of hepatitis C RNA, negative HIV test within 6 weeks prior to study inclusion. * Female patients of child bearing potential (FCBP) and male patients with partners of child bearing potential who are sexually active must agree to the use of two effective forms (at least one highly effective method) of con…